These are reviewed studies whose abstracts concern Ovarian Cancer. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Ovarian Cancer. Most are early lab, animal, or small human studies, and findings often conflict.
ReviewInconclusiveLimited evidenceTier 4 · clinical
Therapeutic advances in medical oncology · Dec 2025 · review
epithelial ovarian cancerhigh-grade serous ovarian cancerovarian clear cell carcinomaendometrioid ovarian carcinomamucinous ovarian carcinomalow-grade serous ovarian carcinomaovarian carcinosarcoma
This review describes the main genomic subtypes of epithelial ovarian cancer and how those differences may help match patients to targeted therapies. It highlights PARP inhibitors, MAPK pathway inhibitors, cell cycle checkpoint inhibitors, immune checkpoint inhibitors, and antibody-drug conjugate approaches that are being investigated for specific ovarian cancer types. The article also notes that resistance to PARP inhibitors remains a problem and that more evidence is needed for effective combination therapies.
Key findings
- High-grade serous ovarian cancer is linked mainly to homologous recombination repair gene alterations such as BRCA1 and BRCA2.
- Ovarian clear cell carcinoma is associated with ARID1A and PIK3CA alterations; endometrioid ovarian carcinoma with PIK3CA and KRAS; mucinous ovarian carcinoma with CDKN2A and KRAS; and low-grade serous ovarian carcinoma with MAPK pathway genes such as BRAF and KRAS.
- PARP inhibitor therapy has improved survival for women with homologous recombination repair defects in high-grade serous ovarian cancer, but acquired resistance remains an issue.
- The review emphasizes that genomically targeted combination therapies are urgently needed and that some reported responses are preliminary.
Limitations: Review article only; no new experimental or clinical data presented in the abstract.; No quantitative outcomes or effect sizes are reported in the abstract.; The abstract is broad and does not provide trial-level details, sample sizes, or follow-up durations.; Some therapies discussed are preliminary and require further evidence..
The article is about ovarian cancer genomics and targeted therapies, not a single compound experiment.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical
Cells · Aug 2025 · review
mucinous ovarian carcinomaovarian cancer
This review summarizes recent treatment ideas and biomarkers for mucinous ovarian carcinoma, a rare type of ovarian cancer. It discusses targeted therapies such as HER2 inhibitors and KRASG12C inhibitors, as well as checkpoint inhibitors and other newer strategies. The abstract does not report results from a new experiment or clinical trial, only a synthesis of the literature.
Key findings
- Mucinous ovarian carcinoma is described as having frequent KRAS mutations and HER2 amplifications.
- The review highlights HER2 inhibitors and KRASG12C inhibitors as targeted therapy options under discussion.
- Checkpoint inhibitors are noted as potentially useful in tumors with high PD-L1 expression or tumor mutational burden.
- The abstract mentions antibody-drug conjugates, synthetic lethality approaches, and Wnt/β-catenin pathway inhibitors as emerging strategies.
Limitations: Review article only; no original patient, animal, or cell-line data in the abstract.; No quantitative outcomes, response rates, or survival data are reported.; The abstract is broad and does not specify which therapies were tested in which settings.; Potential clinical benefit is discussed as promising or potential, not demonstrated in this abstract..
This is a review of therapies and biomarkers in a specific ovarian cancer subtype, not a primary efficacy study.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 381
Lancet (London, England) · Jun 2025 · randomized, controlled, open-label phase 3 trial
Relacorilantplatinum-resistant ovarian cancerepithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase 3 randomized trial tested whether adding relacorilant to nab-paclitaxel helped women with platinum-resistant ovarian cancer. The combination improved progression-free survival and also showed a longer overall survival at an interim analysis. Side effects were similar between groups after accounting for nab-paclitaxel exposure, and no new safety signals were seen.
Reported effects: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 · progression-free survival median 6.54 mo [5.55–7.43], n=188 · +3 more
Studied with: nab-paclitaxel.
Key findings
- Progression-free survival was significantly longer with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone.
- An interim overall survival analysis also favored the combination.
- Adverse events were similar across groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.
Limitations: Open-label design; Overall survival result was based on a planned interim analysis; Trial is ongoing; Funding from the drug manufacturer.
This study evaluated relacorilant as an added anticancer agent in platinum-resistant ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewInconclusiveLimited evidenceTier 4 · clinical
Biomedicines · May 2025 · narrative review
mucinous ovarian carcinomaepithelial ovarian cancer
This review summarizes what is known about mucinous ovarian carcinoma, a rare subtype of ovarian cancer with distinct molecular features such as KRAS mutations and HER2 amplifications. It discusses surgery, fertility-sparing approaches, and adjuvant therapy, and notes that targeted strategies like MEK inhibitors and HER2-directed therapies are being investigated for selected molecular subgroups. The abstract does not report new patient data or trial results.
Key findings
- MOC has frequent KRAS mutations and HER2 amplifications.
- Expansile and infiltrative histologic subtypes may guide lymphadenectomy decisions.
- Fertility-sparing surgery appears safe in FIGO stage IA expansile MOC.
- The role of adjuvant therapy in early-stage disease remains debated because of chemoresistance.
- MEK inhibitors and HER2-directed therapies are under investigation for selected molecular subgroups.
Limitations: Narrative review rather than original study.; No new experimental or clinical outcome data reported in the abstract.; No quantitative effect estimates or trial results provided.; Conclusions depend on heterogeneous retrospective cohorts, molecular studies, and guidelines..
Provides a review of molecularly informed management options for mucinous ovarian carcinoma, including discussion of targeted therapies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 425
Gynecologic oncology · Jan 2025 · retrospective study
This retrospective study looked at 425 tumor samples from people with ovarian, fallopian tube, or primary peritoneal cancers to see how often folate receptor alpha (FRα) was present. FRα was found in 36.3% of cases and was more common in high-grade serous ovarian tumors and in samples from the ovary, fallopian tube, adnexa, or dominant pelvic masses than in metastatic sites. The study also found that some patients had different FRα results in different specimens, suggesting variability in testing results across samples.
Reported effect: positive rates 44.4%, p=0.02
Key findings
- FRα was highly expressed in 36.3% of cases.
- FRα positivity was significantly associated with high-grade serous ovarian histology.
- Samples from the ovary, fallopian tube, adnexa, and dominant pelvic masses had higher FRα positivity than metastatic sites (44.4% vs 32.5%, p = 0.02).
- Time between collection and testing did not impact FRα expression.
- Among 8 patients with more than one specimen tested, 3 (37.5%) had discordant results.
Limitations: Retrospective single-study biomarker analysis.; No treatment outcomes or patient survival endpoints were reported.; Biomarker testing only; does not test mirvetuximab soravtansine efficacy.; Potential sampling and site-related heterogeneity.; Small subgroup with repeated specimens (n=8)..
Useful for understanding FRα testing patterns relevant to selecting patients for FRα-targeted therapy, but it does not evaluate anticancer efficacy.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human trialTrialInconclusiveModerate evidenceTier 4 · clinical
Journal of gynecologic oncology · Jul 2024 · phase 3, randomized, 2-arm, open-label, global multicenter study protocol
Relacorilantadvanced platinum-resistant ovarian cancerrecurrent platinum-resistant high-grade serous epithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This paper describes the ROSELLA phase 3 trial, which is testing relacorilant plus nab-paclitaxel versus nab-paclitaxel alone in women with recurrent platinum-resistant ovarian and related cancers. The study is designed to see whether adding relacorilant improves progression-free survival and other outcomes, and it will also assess safety and patient-reported outcomes. The abstract does not report trial results, only the study plan.
Studied with: nab-paclitaxel.
Key findings
- ROSELLA is a phase 3, randomized, 2-arm, open-label, global multicenter study.
- Participants are assigned 1:1 to relacorilant plus nab-paclitaxel or nab-paclitaxel monotherapy.
- Primary endpoint is progression-free survival assessed by blinded independent central review.
- Secondary endpoints include overall survival, objective response rate, duration of response, clinical benefit rate at 24 weeks, and CA-125 response.
- The abstract reports no efficacy or safety results because it is a trial protocol.
Limitations: Protocol only; no outcomes or results are reported in the abstract.; No sample size is provided in the abstract.; No quantitative effect estimates are available.; Open-label design may introduce bias in some endpoints..
This is a phase 3 protocol in platinum-resistant ovarian cancer evaluating an anticancer combination.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11
Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.
Key findings
- The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
- Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
- Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
- PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
- For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewInconclusiveLimited evidenceTier 4 · clinical
Current treatment options in oncology · Dec 2023 · narrative review
ovarian carcinosarcomaovarian cancer
This review summarizes what is known about ovarian carcinosarcoma, a rare and aggressive ovarian cancer. It discusses risk factors, prognostic markers, and current treatment approaches such as surgery followed by platinum-based chemotherapy, while noting that immunotherapy and HRD testing may be useful in some patients. The article does not report new experimental results from a trial or laboratory study.
Key findings
- Ovarian carcinosarcoma is described as rare and aggressive, with median overall survival under 2 years.
- Poor prognostic factors include advanced stage, older age, lymph node metastasis, suboptimal cytoreduction, heterologous histology, and increased VEGF, p53, and WT1 expression.
- Main treatment approach is cytoreductive surgery followed by platinum-based chemotherapy.
- Immunotherapy is described as promising, and HRD testing may help personalize therapy.
Limitations: Narrative review rather than original research.; No new patient cohort, control group, or quantitative treatment effect data reported in the abstract.; Most evidence discussed is from case reports and small studies.; The abstract does not specify which therapies or biomarkers were evaluated in detail..
Provides an overview of ovarian carcinosarcoma epidemiology, prognosis, and treatment options rather than testing a specific compound.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialMixed resultsModerate evidenceTier 4 · clinicaln = 178
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Oct 2023 · three-arm, randomized, controlled, open-label phase II study
Relacorilantovarian cancerovarian epithelial carcinomaprimary peritoneal cancerfallopian tube cancerovarian carcinosarcoma This phase II study tested relacorilant added to nab-paclitaxel in women with recurrent platinum-resistant or refractory ovarian and related cancers. The intermittent relacorilant schedule improved progression-free survival and duration of response compared with nab-paclitaxel alone, while overall response rate was similar across groups. Side effects were broadly comparable between arms, and the study did not meet its prespecified statistical threshold after multiplicity adjustment.
Reported effects: PFS HR 0.66, p P = .038, n=178 · DOR HR 0.36, p P = .006, n=178 · +1 more
Studied with: nab-paclitaxel.
Key findings
- Intermittent relacorilant plus nab-paclitaxel improved PFS versus nab-paclitaxel monotherapy (HR 0.66; P = .038).
- Intermittent relacorilant plus nab-paclitaxel improved DOR versus nab-paclitaxel monotherapy (HR 0.36; P = .006).
- ORR was similar across arms.
- At the preplanned OS analysis, the OS HR was 0.67 with P = .066 for the intermittent arm versus nab-paclitaxel monotherapy.
- Continuous relacorilant plus nab-paclitaxel showed numerically improved median PFS but no significant improvement over monotherapy.
- Adverse events were comparable across study arms; common grade ≥3 events included neutropenia, anemia, peripheral neuropathy, and fatigue/asthenia.
Limitations: Phase II study with relatively small sample size.; Open-label design.; Primary end point did not reach statistical significance after protocol-prespecified Hochberg step-up multiplicity adjustment.; Median follow-up was limited for PFS and OS analyses.; Safety and efficacy were compared against nab-paclitaxel monotherapy, but the abstract does not provide detailed absolute event rates..
Relacorilant was studied as an add-on to chemotherapy in recurrent platinum-resistant ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical
Heliyon · Aug 2023 · review
mucinous ovarian carcinomaepithelial ovarian cancerovarian mucinous tumors
This review discusses mucins in mucinous ovarian carcinoma and related ovarian mucinous tumors. It says mucins are linked with the development of this cancer and may help distinguish primary from secondary ovarian mucinous tumors. The abstract also notes that some mucins have been studied for chemoresistance and targeted therapy, but it does not report new experimental or clinical results.
Key findings
- Mucins are correlated with mucinous ovarian carcinoma development.
- Mucins may be useful in the differential diagnosis of primary and secondary ovarian mucinous tumors.
- Some mucins have been studied in the context of chemoresistance and targeted therapy for ovarian cancer.
Limitations: Review article only; no original experimental or clinical data in the abstract.; No quantitative outcomes reported.; No specific mucin, intervention, or patient cohort is evaluated in the abstract..
The review is about mucins in mucinous ovarian carcinoma, mainly as biomarkers and in chemoresistance/targeted therapy context.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportTrialReported positiveLimited evidenceTier 3 · early humann = 1
Cureus · Apr 2023 · case report
ovarian carcinosarcomaovarian cancer
This case report describes a 64-year-old woman with stage III ovarian carcinosarcoma who had debulking surgery and adjuvant chemotherapy, then received immunotherapy. The authors report encouraging outcomes after immunotherapy. The report also says microsatellite instability testing may help guide treatment decisions in this type of ovarian cancer.
Studied with: debulking surgery, adjuvant chemotherapy.
Key findings
- A single patient with stage III ovarian carcinosarcoma received immunotherapy after surgery and chemotherapy.
- The abstract reports encouraging outcomes after immunotherapy.
- Microsatellite instability testing was highlighted as potentially useful for guiding treatment decisions.
Limitations: Single-patient case report; No control group; No quantitative outcome data in the abstract; Cannot separate the effect of immunotherapy from surgery and chemotherapy; Abstract does not specify the immunotherapy agent or regimen.
This is a case report of immunotherapy use in ovarian carcinosarcoma, a cancer context, but the abstract does not identify a specific repurposed drug or natural compound.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewTrialReported positiveModerate evidenceTier 4 · clinical
Drugs · Jul 2021 · review article summarizing drug development and approval
Fuzuloparibovarian cancerfallopian tube cancerprimary peritoneal cancersolid cancerspancreatic cancerbreast cancerprostate cancerlung cancer This review describes fuzuloparib, an oral PARP inhibitor, and its development leading to approval in China. The approval was for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with a germline BRCA mutation after second-line or later chemotherapy. The abstract also notes that phase II and III trials are ongoing in other solid cancers.
Key findings
- Fuzuloparib is an orally active PARP inhibitor.
- It has been approved in China for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with germline BRCA mutation after second-line or above chemotherapy.
- Phase II and III trials are investigating it in other solid cancers.
Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..
This is a drug approval review focused on fuzuloparib's use in ovarian and related cancers, not an experimental efficacy study.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text